Orchard Therapeutics plc American Depositary Shares
ORTX
ORTX was delisted on the 23rd of January, 2024.
62 hedge funds and large institutions have $39.8M invested in Orchard Therapeutics plc American Depositary Shares in 2022 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 14 increasing their positions, 16 reducing their positions, and 18 closing their positions.
13% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 16
14% less funds holding
Funds holding: 72 → 62 (-10)
50% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 18
53% less capital invested
Capital invested by funds: $84.6M → $39.8M (-$44.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$1.22M |
| 2 |
SG Americas Securities
New York
|
+$395K |
| 3 |
BlackRock
New York
|
+$122K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$53.2K |
| 5 |
FA
Forefront Analytics
West Conshohocken,
Pennsylvania
|
+$46.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$4.39M |
| 2 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$1.76M |
| 3 |
CA
CHI Advisors
New York
|
-$1.12M |
| 4 |
Two Sigma Investments
New York
|
-$716K |
| 5 |
New York State Common Retirement Fund
Albany,
New York
|
-$620K |
ORTX Hedge Fund Activity: Q1 2022 in Review
62 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Orchard Therapeutics plc American Depositary Shares (ORTX) for Q1 2022, worth a combined $39.8M — down 53% from $84.6M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of ORTX and 9 opened new positions — a net loss of 9 holders — while 16 trimmed existing stakes and 14 added.
The largest buyer was UBS O'Connor, opening a new position worth an estimated $1.22M. The largest seller was Artisan Partners, cutting an estimated $4.39M.
- 62 institutional investors held Orchard Therapeutics plc American Depositary Shares (ORTX) as of Q1 2022, down from 72 in Q4 2021.
- Funds reported $39.8M of Orchard Therapeutics plc American Depositary Shares stock for Q1 2022, down 53% quarter-over-quarter.
- 9 funds opened new Orchard Therapeutics plc American Depositary Shares positions in Q1 2022 and 18 closed out, a net change of -9 holders.
- The largest Orchard Therapeutics plc American Depositary Shares buyer in Q1 2022 was UBS O'Connor, an estimated $1.22M added.
- The largest Orchard Therapeutics plc American Depositary Shares seller in Q1 2022 was Artisan Partners, an estimated $4.39M sold.
Based on aggregated 13F filings for Q1 2022.